Are users of sulphonylureas at the time of an acute coronary syndrome at risk of poorer outcomes?. Issue 11 (3rd June 2013)

• Record Type: Journal Article
• Authors: Nagendran, J.; Oudit, G. Y.; Bakal, J. A.; Light, P. E.; Dyck, J. R. B.; McAlister, F. A.
• Is Part Of: Diabetes, obesity & metabolism. Volume 15:Issue 11(2013:Nov.)
• Page Start: 1022
• Page End: 1028
• Publication Date: 2013-06-03
• Subjects: Diabetes -- Periodicals; Obesity -- Periodicals; Metabolism -- Disorders -- Periodicals; Clinical pharmacology -- Periodicals; 616.462
• DOI: 10.1111/dom.12126
• Languages: English
• ISSNs: 1462-8902

Abstract

<abstract abstract-type="main" id="dom12126-abs-0001"> <title>Abstract</title> <sec id="dom12126-sec-0001" sec-type="section"> <title>Aims</title> <p id="dom12126-para-0001">Adenosine triphosphate sensitive potassium (K<sub>ATP</sub>) channel activity is cardioprotective during ischaemia. One of the purported mechanisms for sulphonylurea adverse effects is through inhibition of these channels. The purpose of this study is to examine whether patients using K<sub>ATP</sub> channel inhibitors at the time of an acute coronary syndrome are at greater risk of death or heart failure (HF) than those not exposed.</p> </sec> <sec id="dom12126-sec-0002" sec-type="section"> <title>Methods</title> <p id="dom12126-para-0002">Using linked administrative databases we identified all adults who had an acute coronary syndrome between April 2002 and October 2006 (n = 21 023).</p> </sec> <sec id="dom12126-sec-0003" sec-type="section"> <title>Results</title> <p id="dom12126-para-0003">Within 30 days of acute coronary syndrome, 5.3% of our cohort died and 15.6% were diagnosed with HF. Individuals with diabetes exhibited significantly higher risk of death (adjusted OR: 1.20, 95% CI: 1.03–1.40) and death or HF (aOR: 1.73, 95% CI: 1.59–1.89) than individuals without diabetes. However, there was no significantly increased risk of death (aOR: 1.00, 95% CI: 0.76–1.33) or death/HF (aOR: 1.06, 95% CI: 0.89–1.26) in patients exposed to K<sub>ATP</sub> channel inhibitors versus patients not exposed to K<sub>ATP</sub> channel inhibitors prior to their acute coronary syndrome.</p> </sec> <sec id="dom12126-sec-0004" sec-type="section"> <title>Conclusions</title> <p id="dom12126-para-0004">Diabetes is associated with an increased risk of death or HF within 30 days of an acute coronary syndrome. However, we did not find any excess risk of death or HF associated with use of K<sub>ATP</sub> channel inhibitors at the time of an acute coronary syndrome, raising doubts about the hypothesis that sulphonylureas inhibit the cardioprotective effects of myocardial K<sub>ATP</sub> channels.</p> </sec> </abstract>